Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Emergent BioSolutions Inc. (EBS) | State

THE ANGEL, May 7, 2021 / PRNewswire / – Glancy Prongay & Murray LLP (“GPM”) reminds investors of the impending development June 18, 2021 Deadline for filing a lead plaintiff motion on behalf of investors who have acquired or otherwise acquired common stock of Emergent BioSolutions Inc. (“Emergent” or the “Company”) (NYSE: EBS) between them July 6, 2020 and March 31, 2021including (the “Class Period”).

If you have suffered a loss on your emergent investments or would like to inquire about whether you may be able to make claims to recover your loss under federal securities laws, you can find your contact information at https://www.glancylaw.com/cases / submit emergent-biosolutions -inc /. You can also contact Charles H. Linehan, from GPM at 310-201-9150, toll free at 888-773-9224, or email [email protected] to learn more about your rights.

On March 31, 2021, The New York Times published an article reporting on it late February 2021, Emergent’s Employee Baltimore The ingredients of the various COVID-19 vaccines were “mixed” at the manufacturing facility, contaminating up to 15 million doses of Johnson & Johnson’s (“J&J”) vaccine, forcing regulators to approve the production line Delay plant.

On April 1, 2021The Associated Press reported on Emergent’s “History of Violations”, noting that the United States Food and Drug Administration (“FDA”) has repeatedly reported Emergent because of problems such as poorly trained staff, cracked vials, and problems dealing with mold and others Cited contamination in their facilities.

On April 3, 2021, The New York Times reported that the Biden administration had appointed J&J to run Emergent Baltimore and banned him from making the AstraZeneca vaccine, a setback for a company that only months earlier had touted its “unique” willingness and “proven ability to manufacture”.

In the news, the company’s share price fell $ 14.29 per share or over 15% in two consecutive trading sessions to close $ 78.62 per share on April 5, 2021.

The complaint filed in this class action alleges that throughout the collection period the defendants made materially false and / or misleading statements and did not disclose material adverse facts about the business, business and prospects of the company. In particular, Defendants have failed to advise investors that: (1) Emergent’s Baltimore The plant has had manufacturing issues in the past, increasing the likelihood of massive contamination. (2) These long-standing contamination risks and quality control issues at Emergent’s facility resulted in a number of FDA citations. (3) The company previously had the equivalent of millions of doses of COVID-19 vaccines according to workers at the Baltimore Plant deviated from manufacturing standards; and (4) as a result, Defendants’ positive statements about the Company’s business, operations and prospects were materially misleading and / or were unfounded at all relevant times.

Follow us for updates on LinkedIn, Twitter or Facebook.

If you purchased or otherwise acquired Emergent common stock during the class period, you may move to court at the latest June 18, 2021 to seek appointment as the lead plaintiff in this alleged class action lawsuit. To be a member of the class action, you do not need to take any action at this point. You can keep an attorney of your choice or you can take no action and remain an absent member of the class action. If you would like to learn more about this class action or have any questions about this announcement or your rights or interests in relation to the pending class action, please contact Charles Linehan, Esquire, by GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, toll free at 888-773-9224, email [email protected], or visit our website at www.glancylaw.com. When inquiring by email, please include your postal address, telephone number and the number of shares purchased.

This press release may be viewed as a solicitor advertisement in some jurisdictions under applicable laws and ethical rules.

To download multimedia, view the original content at: http://www.prnewswire.com/news-releases/glancy-prongay–murray-llp-reminds-investors-of-looming-deadline-in-the-class- action-lawsuit- gegen-emergent-biosolutions-inc-ebs-301286442.html

SOURCE Glancy Prongay & Murray LLP

Comments are closed.